Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 273 clinical trials
Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

Open-label, multi-center, non-randomized, multiple dose, safety, tolerability, pharmacokinetic, and pharmacodynamics and clinical activity study of PF-06940434 (Integrin alpha-V/beta-8 Antagonist) in patients with SCCHN (Squamous Cell Carcinoma of the Head and Neck), renal cell carcinoma (RCC - clear cell and papillary), ovarian, gastric, esophageal, esophageal (adeno and squamous), lung squamous cell, …

squamous cell carcinoma
head and neck carcinoma
squamous cell carcinoma of head and neck
pf-06801591
programmed cell death 1 ligand 1
  • 36 views
  • 07 Oct, 2022
  • 16 locations
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475).

neuroendocrine tumor
small cell carcinoma
endometrial carcinoma
squamous cell carcinoma of cervix
adenocarcinoma
  • 15 views
  • 04 Oct, 2022
  • 24 locations
A Multicenter, Open-label, Phase 2 Basket Study of MK-7684A, a Co-formation of Vibostolimab (MK-7684) With Pembrolizumab (MK-3475), With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected advanced solid tumors. The primary hypothesis is that pembrolizumab/vibostolimab co-formulation is superior to pembrolizumab alone in terms of objective response rate or …

fluorouracil
adenosquamous carcinoma
paclitaxel
ovarian cancer
adenocarcinoma
  • 1 views
  • 24 Oct, 2022
  • 64 locations
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

tumors) (closed to accrual) Clear cell endometrial cancer Clear cell ovarian cancer (closed to accrual) Gestational trophoblastic disease (GTD) Gallbladder cancer

beta-human chorionic gonadotropin
infertility
human immunodeficiency virus
neuroendocrine tumor
thyroidectomy
  • 6651 views
  • 22 Oct, 2022
  • 752 locations
Prevention of Obesity-related Cancers: Setting up of a Multi-Cancer Education and Prevention Program in Hong Kong

Obesity could increase the risk of many chronic diseases, including hypertension, cardiovascular diseases, high lipid level, diabetes, stroke, endometrial cancer and certain types of cancer

chronic disease
prostate specific antigen
overweight or obesity
weight control
cancer screening
  • 24 views
  • 14 Feb, 2022
  • 1 location
Onco-primary Care Networking to Support TEAM-based Care (ONE TEAM)

The proposed ONE TEAM Study is an 18-month, cluster randomized controlled trial. This study will use a sequential multiple assignment randomized trial (SMART) design with a second randomization for the intervention group using a dynamic treatment regimen approach. The investigators propose to randomize 800 adults with newly-diagnosed selected cancers treated …

chronic disease
hypercholesterolemia
type 2 diabetes mellitus
lung cancer
primary cancer
  • 0 views
  • 09 Jun, 2022
  • 1 location
A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PETRA)

This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.

parp inhibitor
cancer
carboplatin
paclitaxel
antineoplastic
  • 18 views
  • 17 Oct, 2022
  • 30 locations
Molecular Analysis for Therapy Choice (MATCH)

This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic …

taselisib
human immunodeficiency virus
white blood cells
absolute neutrophil count
neutrophil count
  • 6595 views
  • 20 Oct, 2022
  • 906 locations
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of INCB099318 in select solid tumors.

  • 0 views
  • 04 Oct, 2022
  • 23 locations
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of INCB099318 in select solid tumors.

  • 1 views
  • 04 Oct, 2022
  • 23 locations